From the Sarcoma Foundation of America

The Medical Advisory Board of the Sarcoma Foundation of America includes the following leading oncologist authorities on sarcomas. More information are their treatment centers can be found at https://www.curesarcoma.org/patient-resources/sarcoma-treatment-centers/

Co-Chair: George Demetri, MD, Dana-Farber Cancer Institute
Co-Chair: Raphael Pollock, MD, PhD, The Ohio State University
Mark Agulnik, MD, FRCPC, Robert H. Lurie Comprehensive Cancer Center
Charles Forscher, MD, Cedars-Sinai Medical Center
John M. Goldberg, MD, H3 Biomedicine
Richard Gorlick, MD, MD Anderson Cancer Center
Lee Helman, MD, University of Southern California/Children’s Hospital Los Angeles
Eugenie S. Kleinerman, MD, MD Anderson Cancer Center
Andrew S. Kraft, MD, University of Arizona Cancer Center
Marc Ladanyi, MD, Memorial Sloan-Kettering Cancer Center
David M. Loeb, MD, PhD, Children’s Hospital at Montefiore
Crystal Mackall, MD, Stanford Cancer Institute
Robert Maki, MD, PhD, Cold Spring Harbor Laboratory
Paul A. Meyers, MD, Memorial Sloan-Kettering Cancer Center
Alberto Pappo, MD, St. Jude Children’s Research Hospital
Shreyaskumar Patel, MD, MD Anderson Cancer Center
Peter Pisters, MD, University Health Network
R. Lor Randall, MD, FACS, Huntsman Cancer Center, University of Utah
Richard F. Riedel, MD, Duke University Medical Center
Scott Schuetze, MD, University of Michigan
Samuel Singer, MD, Memorial Sloan-Kettering Cancer Center
Poul HB Sorensen, MD, PhD, University of British Columbia
William D. Tap, MD, Memorial Sloan-Kettering Cancer Center
Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center
Matt van de Rijn, MD, Stanford School of Medicine

The Medical Advisory Board of the Sarcoma Foundation of America includes the following leading oncologist authorities on sarcomas. More information are their treatment centers can be found at https://www.curesarcoma.org/patient-resources/sarcoma-treatment-centers/

Co-Chair: George Demetri, MD, Dana-Farber Cancer Institute
Co-Chair: Raphael Pollock, MD, PhD, The Ohio State University
Mark Agulnik, MD, FRCPC, Robert H. Lurie Comprehensive Cancer Center
Charles Forscher, MD, Cedars-Sinai Medical Center
John M. Goldberg, MD, H3 Biomedicine
Richard Gorlick, MD, MD Anderson Cancer Center
Lee Helman, MD, University of Southern California/Children’s Hospital Los Angeles
Eugenie S. Kleinerman, MD, MD Anderson Cancer Center
Andrew S. Kraft, MD, University of Arizona Cancer Center
Marc Ladanyi, MD, Memorial Sloan-Kettering Cancer Center
David M. Loeb, MD, PhD, Children’s Hospital at Montefiore
Crystal Mackall, MD, Stanford Cancer Institute
Robert Maki, MD, PhD, Cold Spring Harbor Laboratory
Paul A. Meyers, MD, Memorial Sloan-Kettering Cancer Center
Alberto Pappo, MD, St. Jude Children’s Research Hospital
Shreyaskumar Patel, MD, MD Anderson Cancer Center
Peter Pisters, MD, University Health Network
R. Lor Randall, MD, FACS, Huntsman Cancer Center, University of Utah
Richard F. Riedel, MD, Duke University Medical Center
Scott Schuetze, MD, University of Michigan
Samuel Singer, MD, Memorial Sloan-Kettering Cancer Center
Poul HB Sorensen, MD, PhD, University of British Columbia
William D. Tap, MD, Memorial Sloan-Kettering Cancer Center
Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center
Matt van de Rijn, MD, Stanford School of Medicine

The Medical Advisory Board of the Sarcoma Foundation of America includes the following leading oncologist authorities on sarcomas. More information are their treatment centers can be found at https://www.curesarcoma.org/patient-resources/sarcoma-treatment-centers/

Co-Chair: George Demetri, MD, Dana-Farber Cancer Institute
Co-Chair: Raphael Pollock, MD, PhD, The Ohio State University
Mark Agulnik, MD, FRCPC, Robert H. Lurie Comprehensive Cancer Center
Charles Forscher, MD, Cedars-Sinai Medical Center
John M. Goldberg, MD, H3 Biomedicine
Richard Gorlick, MD, MD Anderson Cancer Center
Lee Helman, MD, University of Southern California/Children’s Hospital Los Angeles
Eugenie S. Kleinerman, MD, MD Anderson Cancer Center
Andrew S. Kraft, MD, University of Arizona Cancer Center
Marc Ladanyi, MD, Memorial Sloan-Kettering Cancer Center
David M. Loeb, MD, PhD, Children’s Hospital at Montefiore
Crystal Mackall, MD, Stanford Cancer Institute
Robert Maki, MD, PhD, Cold Spring Harbor Laboratory
Paul A. Meyers, MD, Memorial Sloan-Kettering Cancer Center
Alberto Pappo, MD, St. Jude Children’s Research Hospital
Shreyaskumar Patel, MD, MD Anderson Cancer Center
Peter Pisters, MD, University Health Network
R. Lor Randall, MD, FACS, Huntsman Cancer Center, University of Utah
Richard F. Riedel, MD, Duke University Medical Center
Scott Schuetze, MD, University of Michigan
Samuel Singer, MD, Memorial Sloan-Kettering Cancer Center
Poul HB Sorensen, MD, PhD, University of British Columbia
William D. Tap, MD, Memorial Sloan-Kettering Cancer Center
Jonathan Trent, MD, PhD, Sylvester Comprehensive Cancer Center
Matt van de Rijn, MD, Stanford School of Medicine

The Sarcoma Foundation of America offers patient resources that explain what sarcoma is, the various subtypes, how sarcomas are diagnosed, and treatment options. Information is available online at https://www.curesarcoma.org/patient-resources/

The Sarcoma Foundation of America offers patient resources that explain what sarcoma is, the various subtypes, how sarcomas are diagnosed, and treatment options. Information is available online at https://www.curesarcoma.org/patient-resources/

The Sarcoma Foundation of America offers patient resources that explain what sarcoma is, the various subtypes, how sarcomas are diagnosed, and treatment options. Information is available online at https://www.curesarcoma.org/patient-resources/

The Sarcoma Foundation of America has developed a program to provide grants to investigators interested in translational science sarcoma research.  Funding of up to $50,000, allowing up to 10 percent indirect costs, is available to cover equipment and supplies in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas.

In accordance with the mission of the Foundation, research involving the development of novel agents against sarcoma, or research that could potentially lead to the development of novel agents against sarcoma, is eligible for this funding.

Please refer to SFA's Grants FAQ for additional information.

Researchers must submit proposals electronically at proposalCENTRAL.  First-time users will be required to register and complete a professional profile in order to apply for an SFA research grant.  The SFA does not accept applications via e-mail.

For more information, visit the SFA website at https://www.curesarcoma.org/research/apply-for-a-grant/

The Sarcoma Foundation of America has developed a program to provide grants to investigators interested in translational science sarcoma research.  Funding of up to $50,000, allowing up to 10 percent indirect costs, is available to cover equipment and supplies in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas.

In accordance with the mission of the Foundation, research involving the development of novel agents against sarcoma, or research that could potentially lead to the development of novel agents against sarcoma, is eligible for this funding.

Please refer to SFA's Grants FAQ for additional information.

Researchers must submit proposals electronically at proposalCENTRAL.  First-time users will be required to register and complete a professional profile in order to apply for an SFA research grant.  The SFA does not accept applications via e-mail.

For more information, visit the SFA website at https://www.curesarcoma.org/research/apply-for-a-grant/

The Sarcoma Foundation of America has developed a program to provide grants to investigators interested in translational science sarcoma research.  Funding of up to $50,000, allowing up to 10 percent indirect costs, is available to cover equipment and supplies in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas.

In accordance with the mission of the Foundation, research involving the development of novel agents against sarcoma, or research that could potentially lead to the development of novel agents against sarcoma, is eligible for this funding.

Please refer to SFA's Grants FAQ for additional information.

Researchers must submit proposals electronically at proposalCENTRAL.  First-time users will be required to register and complete a professional profile in order to apply for an SFA research grant.  The SFA does not accept applications via e-mail.

For more information, visit the SFA website at https://www.curesarcoma.org/research/apply-for-a-grant/

The Sarcoma Foundation of America is a national organization dedicated to increasing sarcoma awareness and research. Through its advocacy and fundraising efforts, the foundation has supported 115 sarcoma research grants since 2003, along with two large American Society of Clinical Oncology (ASCO) Foundation Clinical Research grants worth $450,000. The SFA has also funded six ASCO Young Investigator Awards and has started a large research based initiative called the Sarcoma Patient Registry, designed to increase research performed on sarcoma and to facilitate clinical trials.

To learn more about the Sarcoma Foundation of America, visit their website.

The Sarcoma Foundation of America is a national organization dedicated to increasing sarcoma awareness and research. Through its advocacy and fundraising efforts, the foundation has supported 115 sarcoma research grants since 2003, along with two large American Society of Clinical Oncology (ASCO) Foundation Clinical Research grants worth $450,000. The SFA has also funded six ASCO Young Investigator Awards and has started a large research based initiative called the Sarcoma Patient Registry, designed to increase research performed on sarcoma and to facilitate clinical trials.

To learn more about the Sarcoma Foundation of America, visit their website.

The Sarcoma Foundation of America is a national organization dedicated to increasing sarcoma awareness and research. Through its advocacy and fundraising efforts, the foundation has supported 115 sarcoma research grants since 2003, along with two large American Society of Clinical Oncology (ASCO) Foundation Clinical Research grants worth $450,000. The SFA has also funded six ASCO Young Investigator Awards and has started a large research based initiative called the Sarcoma Patient Registry, designed to increase research performed on sarcoma and to facilitate clinical trials.

To learn more about the Sarcoma Foundation of America, visit their website.